


Prospect of Targeted Immunological Checkpoint Treatment

Increase Your Efficiency and Value


Antibodies, antigens, *etc.* for your research and discovery



✉ info@creative-biolabs.com

🌐 www.antibody-creativebiolabs.com

Background of Immunotherapy



The Importance of Immunotherapy

The basic idea of tumor immunotherapy is to activate the immune system like a microbial infection to eliminate malignant tumors. Such treatments include monoclonal antibodies, recombinant cytokines, and cellular therapies such as chimeric antigen receptors. With this special immunotherapy, some cancer patients who are not sensitive to other direct therapies have shown good therapeutic effects. Immune checkpoint treatment has significantly better safety than refractory cancers compared to other therapies, and long-term inhibition has been achieved in a small number of patients. These results give cancer patients hope for better control or cure of cancer. In the near future, treatments based on immunological checkpoint treatment will revolutionize cancer treatment.


Current Status of Immunotherapy

To date, based on clinical transformation efforts initiated by Allison and Honjo, the regulatory authorities have approved at least six inhibitory antibodies against the immune checkpoints CTLA-4 and PD-1 and a combination for cancer treatment. The current research has made it clear that they also play a role in different immune response stages.

CTLA-4 mainly affects T helper cells (CD4+ cells) in immune priming reactions. PD-1 inhibits T cell receptor signaling pathways and thus mainly affects effector T cells (CD8+ cells). Combined treatments can achieve better results due to differences in these basic functions.

In fact, there are multiple checkpoints that can stimulate or inhibit the different levels of the immune response, even the entire immune system. Recently, IL-17A inhibitory antibody (Secukinumab) has been successfully used to control the treatment of immune-related adverse reactions.

Immunological checkpoint inhibitors do not have the same therapeutic effect on all tumors.



Challenges and Opportunities for Immunotherapy

Key obstacles to overcome on the path of immunotherapy include the serious side effects that immunotherapy may have, the antagonistic response to immunological checkpoint inhibitor therapy, and how to discover new targets for immunotherapy.

Other immunosuppressive targets, including LAG-3, TIM-3, TIGIT, VISTA, B7/H3 and LILRB4, are being tried for the treatment of cancer. The real changes will be accompanied by the emergence of new generations of this problem. With the advent of cancer therapy with immunological checkpoint inhibitors, some cancers that were previously very limited or incapable of treatment have had surprising effects.

The development of biomarker predictions for immune checkpoint inhibitors is also an important area of research in the future. The emergence of immunological checkpoint inhibitors in the field of cancer treatment is itself a Copernican revolution in cancer treatment.

Reference: *Rios, A., Salazar, G. T. A., Zhang, N., & An, Z. (2019). The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective*



Featured Antibodies for Immunosuppressive Targets


Targets	Clone	Applications	Type	Species Reactivity	Cat.
CTLA-4	BN13	Neut, FC	Mouse IgG2a	Human	CBMAB-0932-LY
CTLA-4	9H10	Neut	Hamster IgG2	Mouse	CBMAB-1010-LY
CTLA-4	9D9	Neut, WB	Mouse IgG2b	Mouse	CBMAB-1009-LY
CTLA-4	4F10	Neut, FC	Hamster IgG	Mouse	CBMAB-1008-LY
CTLA-4	1G7-H10	FC	Mouse IgG2a	Human	CBMAB-Z0100-LY
PD-1	J116	Neut	Mouse IgG1	Human	CBMAB-0943-LY
PD-1	J110	FC	Mouse IgG1	Human	CBMAB-0942-LY
PD-1	IHC001	IHC	Mouse IgG	Human	CBMAB-MA195-YC
PD-1	D7D5W	IF, ICC	Rabbit IgG	Mouse, Rat, Hamster	CBMAB-CP1893-LY
PD-1	6B10	WB, ELISA	Mouse IgG1	Human	CBMAB-A6491-LY
PD-1	NAT105	FC	Mouse IgG1	Human	CBMAB-C12157-LY
PD-1	J105	FC	Mouse IgG1	Human	CBMAB-C4048-CN
PD-1	9A187	IHC, FC	Mouse IgG1	Human	CBMAB-C0427-CN
PD-1	CBWJC-4275	IHC-P, WB	Mouse IgG1	Human	CBMAB-C5632WJ
PD-1	CBWJC-4274	FC, IHC, Blocking	Mouse IgG1	Human	CBMAB-C5631WJ
PD-1	CBWJC-4273	FC, ELISA	Mouse IgG1	Human	CBMAB-C5630WJ
PD-1	CBWJC-2356	FC	Rat IgG2b	Mouse	CBMAB-C3302WJ

Targets	Clone	Applications	Type	Species Reactivity	Cat.
IL-17A	50101	ELISA, WB	Rat IgG2a	Mouse	CBMAB-1355-YC
IL-17A	17F3	Neut	Mouse IgG1	Mouse	CBMAB-1032-LY
IL-17A	D1X7L	WB, IP, FC	Rabbit IgG	Mouse, Rat	CBMAB-CP1151-LY
IL-17A	3G5	ELISA, WB	Mouse IgG2a	Human	CBMAB-A4360-LY
IL-17A	CBYY-I2074	ELISA, LMNX	Mouse IgG1	Human	CBMAB-I3244-YY
IL-17A	CBYY-I1865	ELISpot, ELISA	Rat IgG1	Mouse	CBMAB-I3035-YY
IL-17A	CBYY-I0952	Neut, WB	Rat IgG2	Mouse	CBMAB-I2120-YY
IL-17A	B-B51	ELISA(Det), ELISpot, FuncS, Neut	Mouse IgG2b	Human	CBMAB-I1972-YY
IL-17A	4k5F6	WB, IHC-P, FC	Mouse IgG2a	Human	CBMAB-I1368-YY
IL-17A	CBYY-I0546	WB, IP, FC	Rabbit IgG	Mouse, Rat	CBMAB-I1230-YY
IL-17A	CBFYH-3597	ELISA, FC, WB	Mouse IgG2b	Human	CBMAB-H4151-FY
LAG-3	C9B7W	Neut, FC	Rat IgG1	Mouse	CBMAB-1047-LY
LAG-3	E5S8V	WB	Rabbit IgG	Mouse	CBMAB-CP1332-LY
LAG-3	T47-530	FC	Mouse IgG1	Human	CBMAB-C12005-LY
LAG-3	CBXC-0821	FC	Human IgG1	Human	CBMAB-C3377-CQ
LAG-3	CBYY-C2632	FC	Rat IgG2b	Mouse	CBMAB-C4073-YY
LAG-3	CBYY-C2631	WB	Mouse IgG2a	Human	CBMAB-C4072-YY

Targets	Clone	Applications	Type	Species Reactivity	Cat.
HAVCR2	CBMW-H0539	FC, WB	Mouse IgG1	HAV	CBMAB-V208-0595-FY
HAVCR2	CBMW-H0538	FC, IP	Rat IgG1	HAV	CBMAB-V208-0594-FY
HAVCR2	CBMW-H0536	WB, ELISA	Rat IgG2a	HAV	CBMAB-V208-0592-FY
HAVCR2	CBXC-0907	FC	Human IgG1	Human, Primate	CBMAB-C2022-CQ
HAVCR2	CBYY-C2531	FC	Mouse IgG1	Mouse	CBMAB-C3972-YY
HAVCR2	CBYY-C0698	FC, IHC, IP, FuncS	Rat IgG1	Mouse	CBMAB-C2051-YY
HAVCR2	CBYY-C0577	FC, FuncS	Mouse IgG1	Human	CBMAB-C1811-YY
HAVCR2	RMT3-23	FC, IF, IHC	Rat IgG2a	Mouse	CBMAB-T0384-YJ
HAVCR2	CBYJT-1358	FC, IHC, IP, WB	Rabbit IgG	Human	CBMAB-T0377-YJ
TIGIT	E6L7H	WB, IP	Rabbit IgG	Human	CBMAB-CP2771-LY
TIGIT	13E7	ELISA, IHC, WB	Mouse IgG1	Human, Mouse	CBMAB-XB1141-YC
TIGIT	CBYJT-3145	FC	Rat IgG2a	Mouse	CBMAB-T2416-YJ
TIGIT	CBYJT-3141	FC, CyTOF	Mouse IgG2b	Human	CBMAB-T2412-YJ
TIGIT	CBYJT-3140	FC	Mouse IgG3	Human	CBMAB-T2411-YJ
B7-H3	MJ18	Blocking, FC	Rat IgG1	Mouse	CBMAB-0957-LY
B7-H3	7B9	ELISA	Mouse IgG1	Human	CBMAB-A1251-LY
B7-H3	6E6	ELISA	Mouse IgG2b	Human	CBMAB-A1251-LY

Prospect of Targeted Immunological Checkpoint Treatment

Targets	Clone	Applications	Type	Species Reactivity	Cat.
TIGIT	SP206	FC, WB	Rabbit IgG	Human, Mouse, Rat	CBMAB-C10156-LY
TIGIT	MIH35	FC	Rat IgG2a	Mouse, Human	CBMAB-C10152-LY
LILRB4	ZM4.1	FC	Mouse IgG1	Human	CBMAB-C12020-LY
LILRB4	CBWJC-4124	FC	Hamster IgG	Mouse	CBMAB-C5468WJ
LILRB4	CBXC-0716	FC	Human IgG1	Human	CBMAB-C1830-CQ
LILRB4	CBYY-I1349	ELISA, WB	Mouse IgG2a	Human	CBMAB-I2519-YY




About Us

Since 2004, Creative Biolabs has been working on the development of antibodies against to tumor markers and immunosuppressive targets.

At Creative Biolabs, we utilize advanced antibody research tools, professional technical support, and rapid global delivery to ensure the quality for scientific research workers and customers in industry. We believe that to build up a custom-service-centered business model is crucial for optimizing the drug development process, leveraging accessible resources, and gathering a team from various backgrounds to conduct drug discovery projects in the future.

As a preferred supplier for global customers, we are confident to provide you with first-class services covering a full range of applications. If you have any need for antibodies, please [contact us](#).





Tel: 1-631-381-2994

Fax: 1-631-207-8356



Email: info@creative-biolabs.com

www.antibody-creativebiolabs.com



45-1 Ramsey Road, Shirley, NY 11967, USA



CBPROMISE

Our promise:
Guaranteed product
quality, expert
customer support.